Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Astria Therapeutics Inc (ATXS) is a biopharmaceutical innovator developing monoclonal antibody therapies for rare immunological conditions like hereditary angioedema and atopic dermatitis. This page aggregates all official company announcements and verified news updates for stakeholders tracking its preclinical pipeline and scientific advancements.
Investors and researchers will find timely updates on clinical developments, regulatory milestones, and strategic partnerships. Our curated feed includes progress reports on key candidates like plasma kallikrein inhibitors and OX40 antagonists, along with analyses of their potential impact on underserved patient populations.
Content spans trial design announcements, patent filings, executive commentary, and peer-reviewed research collaborations. All materials are vetted for accuracy and presented in chronological order to help users track the company's evolving position in the rare disease therapeutics market.
Bookmark this page for streamlined access to ATXS's latest scientific disclosures and corporate developments. Check regularly for updates on antibody engineering breakthroughs and preclinical validation studies shaping the future of immune disorder treatments.
Astria Therapeutics (NASDAQ:ATXS) reported final results from the fully enrolled ALPHA-STAR Phase 1b/2 trial of navenibart in hereditary angioedema (HAE) patients (n=29), showing strong efficacy and a favorable safety profile through six months.
Key numeric results: mean/median attack-rate reductions were 84%/93% (Cohort 1, single 450 mg), 90%/100% (Cohort 2, 600 mg then 300 mg), and 92%/100% (Cohort 3, two 600 mg doses). Cohorts 2 and 3 had attack-free rates of 62% and 67%. No serious treatment-emergent adverse events or discontinuations were reported; all 29 patients enrolled in the long-term extension. The Phase 3 ALPHA-ORBIT program is enrolling with topline results expected in early 2027.
Astria Therapeutics (Nasdaq: ATXS) will present final results from the ALPHA-STAR Phase 1b/2 trial of navenibart in hereditary angioedema (HAE) at the American College of Allergy, Asthma, and Immunology Annual Scientific Meeting.
Presenter: Aleena Banerji, M.D., Professor of Medicine at Harvard Medical School and Clinical Director, Allergy and Clinical Immunology at Massachusetts General Hospital. Date & time: Saturday, November 8, 2025 at 12:15 PM EST. Location: e-poster area, West Exhibit Hall, Monitor 23, ACAAI Annual Meeting in Orlando, Florida.
BioCryst (Nasdaq: BCRX) agreed to acquire Astria Therapeutics (Nasdaq: ATXS) for an implied value of $13.00 per ATXS share and about $700 million enterprise value. The deal combines BioCryst’s oral HAE franchise with Astria’s injectable Phase 3 candidate navenibart, which has pivotal ALPHA-ORBIT topline data expected in early 2027. BioCryst expects to remain non-GAAP profitable and cash flow positive after closing and to be accretive to operating profit in the first full year after navenibart launch. Closing is expected in Q1 2026, subject to approvals; Astria stockholders would own ~15% of the combined company.
Astria Therapeutics (NASDAQ:ATXS) will present two posters at the Canadian Society of Allergy and Clinical Immunology (CSACI) 80th Anniversary Scientific Meeting in Vancouver, October 15–18, 2025.
Presenters include Dr. Adil Adatia, sharing initial ALPHA-SOLAR long‑term results on navenibart in hereditary angioedema (HAE), and Kusumam Joseph, Ph.D., presenting details on the global Phase 3 ALPHA-ORBIT trial of navenibart. Both posters will be displayed in the poster hall at Vancouver Convention Centre (East) from 9:00 AM PDT on Oct 16 to 2:45 PM PDT on Oct 18, 2025. The presentations cover long‑term safety, efficacy, quality of life, and Phase 3 trial design for navenibart in HAE.
Astria Therapeutics (NASDAQ:ATXS) announced on October 8, 2025 the initiation of the Phase 3 ORBIT-EXPANSE long-term trial of navenibart for people with hereditary angioedema (HAE).
ORBIT-EXPANSE follows the pivotal ALPHA-ORBIT Phase 3 trial and is designed to support global registration. Eligible participants who complete ALPHA-ORBIT may continue into ORBIT-EXPANSE, where all participants will receive navenibart on Q3M or Q6M regimens. The trial has two parts: Part 1 involves a fixed dosing period of at least 6 months; Part 2 offers a patient-centered flexible dosing period allowing regimen switches. ClinicalTrials.gov identifier: NCT07204938.
Astria Therapeutics (Nasdaq: ATXS) announced presentations at the 2025 HAEi Regional Conference EMEA in Rome, Italy, October 10-12, 2025. The company will present one poster and one oral session on navenibart.
Dr. William Lumry will present a poster on ALPHA-ORBIT (a global Phase 3, randomized, double-blind, placebo-controlled trial) on Oct 10, 2025 at 6:30pm CEST, and an oral presentation sharing initial safety and efficacy data from ALPHA-STAR (Phase 1b/2) on Oct 11, 2025 at 9:45am CEST.
Astria Therapeutics (Nasdaq: ATXS) granted inducement stock options to purchase 173,000 shares on October 1, 2025 under its 2022 Inducement Stock Incentive Plan.
The grants were made as inducement awards to three employees in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $7.54, equal to the closing common stock price on the grant date, and vest over four years: 25% at the first anniversary of employment (which preceded the grant date) and the remainder monthly over 36 months, subject to continued employment and the plan/award agreement terms.
Astria Therapeutics (NASDAQ:ATXS) has expanded enrollment for its Phase 3 ALPHA-ORBIT trial of navenibart, a monoclonal antibody treatment for hereditary angioedema (HAE), to include clinical sites in the European Union. The trial, which received European Medicines Agency (EMA) approval, will activate 32 sites across 10 EU countries.
The global Phase 3 pivotal trial will evaluate navenibart's efficacy and safety in up to 145 participants with HAE Type 1 or Type 2, with dosing intervals of 3 or 6 months. The study's primary endpoint focuses on monthly HAE attacks at 6 months, while a key secondary endpoint measures the proportion of attack-free participants.
Following 6 months in ALPHA-ORBIT, eligible participants may enter the ORBIT-EXPANSE long-term trial, featuring patient-centered flexible dosing.
Astria Therapeutics (Nasdaq:ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, has granted inducement stock options to three new employees. The options allow purchase of 128,000 shares at an exercise price of $6.59 per share, matching the closing price on September 2, 2025.
The options, granted under Astria's 2022 Inducement Stock Incentive Plan, will vest over four years with 25% vesting after one year and the remainder vesting monthly over the following 36 months, contingent on continued employment.
Astria Therapeutics (NASDAQ:ATXS) has announced it will present initial Phase 1a trial data for STAR-0310, their long-acting OX40 receptor antagonist, at the upcoming EADV Congress 2025 in Paris. The presentation will be delivered by Dr. Stephan Weidinger, Director of Dermatology and Allergy at the University Medical Center Kiel, on September 17, 2025.
The late-breaking oral presentation will focus on early proof-of-concept data, including safety, pharmacokinetics (PK), and pharmacodynamics (PD) results from healthy participants in the Phase 1a trial.
FAQ
What is the current stock price of Astria Therapeutics (ATXS)?
What is the market cap of Astria Therapeutics (ATXS)?
